Xin Yao

Tianjin Medical University

Tianjin, 300060

China

SCHOLARLY PAPERS

1

DOWNLOADS

69

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (1)

1.

Efficacy and Safety of RC48-ADC, a Her2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: A Phase 2, Open-Label, Multi-Centre, Single-Arm Study

Number of pages: 118 Posted: 02 Oct 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Chinese Academy of Medical Sciences - State Key Lab of Molecular Oncology, Sun Yat-sen University (SYSU) - Department of Medical Oncology, Tianjin Medical University, Chongqing University, Shandong University - Qilu Hospital, Sichuan University - Department of Medical Oncology, Peking University - Department of Urology, Government of the People's Republic of China - Weifang No. 2 People's Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Pathology, Central South University - Affiliated Cancer Hospital, Anhui Provincial Cancer Hospital, Chinese Academy of Medical Sciences - National Cancer Center, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, RemeGen, Ltd., Chinese Academy of Medical Sciences - State Key Lab of Molecular Oncology and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 69 (446,579)

Abstract:

Loading...